WO2023042097 - ANTIBODY-DRUG CONJUGATE FOR USE IN METHODS OF TREATING CHEMOTHERAPY-RESISTANT CANCER
National phase entry:
Publication Number
WO/2023/042097
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058672
International Filing Date
14.09.2022
Title **
[English]
ANTIBODY-DRUG CONJUGATE FOR USE IN METHODS OF TREATING CHEMOTHERAPY-RESISTANT CANCER
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT DESTINÉ À ÊTRE UTILISÉ DANS DES MÉTHODES DE TRAITEMENT DE CANCER RÉSISTANT À LA CHIMIOTHÉRAPIE
Applicants **
DAIICHI SANKYO COMPANY, LIMITED
3-5-1, Nihonbashi Honcho, Chuo-ku
Tokyo, 103-8426, JP
Inventors
NAGASE, Shotaro
c/o DAIICHI SANKYO COMPANY, LIMITED
3-5-1, Nihonbashi Honcho, Chuo-ku
Tokyo, 103-8426, JP
SAITO, Chiemi
c/o DAIICHI SANKYO COMPANY, LIMITED
3-5-1, Nihonbashi Honcho, Chuo-ku
Tokyo, 103-8426, JP
SUZUKI, Hirokazu
c/o DAIICHI SANKYO COMPANY, LIMITED
3-5-1, Nihonbashi Honcho, Chuo-ku
Tokyo, 103-8426, JP
Priority Data
63/244,458
15.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4794 | |
| EPO | Filing, Examination | 22615 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 11410 |
Total: 39988 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to the field of therapeutic methods for treating a cancer using an ADC. The present disclosure also relates to the field of pharmaceutical products comprising the ADC for treating a cancer. More specifically, the ADC is composed of an anti-cadherin-6 (CDH6) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor, and the cancer may be resistant to chemotherapy.[French]
La présente divulgation concerne le domaine des méthodes thérapeutiques destinées au traitement d'un cancer à l'aide d'un ADC. La présente divulgation concerne également le domaine des produits pharmaceutiques comprenant l'ADC destiné à traiter un cancer. Plus spécifiquement, l'ADC est composé d'un anticorps anti-cadhérine-6 (CDH6), relié par l'intermédiaire d'un lieur à un agent anticancéreux, tel qu'un inhibiteur de la topo-isomérase I, et le cancer peut être résistant à la chimiothérapie.